Epigenetic modulation of Fgf21 in the perinatal mouse liver ameliorates diet-induced obesity in adulthood by Yuan Xunmei et al.
Epigenetic modulation of Fgf21 in the
perinatal mouse liver ameliorates diet-induced
obesity in adulthood
著者 Yuan Xunmei, Tsujimoto Kazutaka, Hashimoto
Koshi, Kawahori Kenichi, Hanzawa Nozomi,
Hamaguchi Miho, Seki Takami, Nawa Makiko,
Ehara Tatsuya, Kitamura Yohei, Hatada Izuho,
Konishi Morichika, Itoh Nobuyuki, Nakagawa
Yoshimi, Shimano Hitoshi, Takai-Igarashi
Takako, Kamei Yasutomi, Ogawa Yoshihiro
journal or
publication title
Nature communications 
volume 9
page range 636
year 2018-02
権利 (C) The Author(s) 2018 
This article is licensed under a Creative
Commons Attribution 4.0 International License,
which permits use, sharing, adaptation,
distribution and reproduction in any medium or
format, as long as you give appropriate credit
to the original author(s) and the source,
provide a link to the Creative Commons
license, and indicate if changes were made.
The images or other third party material in
this article are included in the article ’ s
Creative Commons license, unless indicated
otherwise in a credit line to the material. If
material is not included in the article ’ s
Creative Commons license and your intended use
is not permitted by statutory regulation or
exceeds the permitted use, you will need to
obtain permission directly from the copyright
holder. To view a copy of this license, visit
http://creativecommons.org/ licenses/by/4.0/
URL http://hdl.handle.net/2241/00151179
doi: 10.1038/s41467-018-03038-w
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
ARTICLE
Epigenetic modulation of Fgf21 in the perinatal
mouse liver ameliorates diet-induced obesity in
adulthood
Xunmei Yuan1,14, Kazutaka Tsujimoto1, Koshi Hashimoto2, Kenichi Kawahori1, Nozomi Hanzawa1,
Miho Hamaguchi1,14, Takami Seki1, Makiko Nawa3, Tatsuya Ehara1,4, Yohei Kitamura4, Izuho Hatada5,
Morichika Konishi6, Nobuyuki Itoh7, Yoshimi Nakagawa 8,9, Hitoshi Shimano8,9, Takako Takai-Igarashi10,
Yasutomi Kamei11 & Yoshihiro Ogawa1,12,13,14
The nutritional environment to which animals are exposed in early life can lead to epigenetic
changes in the genome that inﬂuence the risk of obesity in later life. Here, we demonstrate
that the ﬁbroblast growth factor-21 gene (Fgf21) is subject to peroxisome proliferator-
activated receptor (PPAR) α–dependent DNA demethylation in the liver during the postnatal
period. Reductions in Fgf21 methylation can be enhanced via pharmacologic activation of
PPARα during the suckling period. We also reveal that the DNA methylation status of Fgf21,
once established in early life, is relatively stable and persists into adulthood. Reduced DNA
methylation is associated with enhanced induction of hepatic FGF21 expression after PPARα
activation, which may partly explain the attenuation of diet-induced obesity in adulthood. We
propose that Fgf21 methylation represents a form of epigenetic memory that persists into
adulthood, and it may have a role in the developmental programming of obesity.
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Nutritional experiences in early life have a long-lastinginﬂuence on the development of body weight, thusaffecting the risk of obesity in later life1,2. For instance,
malnutrition in early life as a result of poor nutrition during
pregnancy and/or the lactation period may be stored onto the
offspring genome as memory. It may persist into adulthood,
thereby increasing the susceptibility to metabolic diseases such as
obesity in later life, which has been referred to as developmental
programming or the “developmental origins of health and disease
(DOHaD)” hypothesis1,3,4.
Epigenetic modiﬁcations represent a prime candidate
mechanism to explain the long-lasting inﬂuence on metabolic
phenotypes such as obesity5. Indeed, a considerable amount of
evidence has recently been accumulated regarding the role of
epigenetic dysregulation in human obesity6–8.
The methylation of cytosine residues in CpG dinucleotides (i.e.,
cytosine followed by guanine) or DNA methylation is a major
epigenetic modiﬁcation known to suppress gene transcription.
Cell type-speciﬁc patterns of CpG methylation are mitotically
inherited, as well as highly stable in differentiated cells and tis-
sues9–11. Accordingly, most epigenetic studies concerning the
developmental programming of obesity focused on DNA
methylation. However, whether DNA methylation status of a
particular gene, when established in early life, can inﬂuence the
developmental programming of obesity is currently unknown.
On the contrary, we previously reported that DNA methylation
status of metabolic genes in the liver dynamically changes in early
life, even during the suckling period, thus sequentially activating
hepatic metabolic function to adapt to the nutritional
environment12,13.
In the previous report, we found that upon the onset of lac-
tation after birth, milk serves as a ligand to activate the nuclear
receptor peroxisome proliferator-activated receptor (PPAR)α,
which is a key transcriptional regulator of hepatic lipid metabo-
lism mediating the adaptive response to energy store13,14,15.
PPARα activation via milk lipid ligands physiologically leads to
DNA demethylation of fatty-acid β-oxidation genes in the post-
natal mouse liver13. Given that PPARα may act as a sensor of
milk lipids during the suckling period16,17, it is likely that
PPARα-dependent DNA demethylation primes the activation of
the fatty-acid β-oxidation pathway in the liver, thereby con-
tributing to the efﬁcient production of energy from milk lipids.
We also demonstrated that administration of a synthetic PPARα
ligand to mouse dams during the perinatal period induces
enhanced reductions in DNA methylation of fatty-acid β-oxida-
tion genes in the liver of the offspring, suggesting that DNA
methylation status of hepatic metabolism-related genes can be
modulated via ligand-activated PPARα during the perinatal per-
iod. Therefore, these ﬁndings prompted us to explore whether
DNA methylation status of PPARα target genes, which is
modulated and established in a PPARα-dependent manner in
early life, persists into adulthood, and if so, we sought to clarify
how these changes inﬂuence adult metabolic phenotypes such as
obesity.
Using a genome-wide analysis of DNA methylation, we iden-
tiﬁed a few PPARα target genes that underwent ligand-activated
PPARα-dependent DNA demethylation during the perinatal
period and whose DNA hypomethylation status persists into
adulthood. Among these genes, which can be referred to as epi-
genetic memory genes, we focused on ﬁbroblast growth factor 21
(FGF21), a bona ﬁde PPARα target gene, which is a major
hepatocyte-derived hormone implicated in the regulation of
energy homeostasis and body weight through its effect on mul-
tiple target organs including adipose tissue18–20.
In this study, we provide the ﬁrst evidence that the PPARα-
dependent Fgf21 demethylation occurs in the postnatal mouse
liver. Importantly, Fgf21 methylation status can be modulated in
early life, and once established it persists into adulthood and
exerts long-term effects on the magnitude of gene expression
response to environmental cues, which may account in part for
the attenuation of diet-induced obesity.
Results
Genome-wide analysis of PPARα-dependent DNA demethyla-
tion. In a previous study, we found that maternal administration
of a synthetic PPARα ligand (Wy 14643, Wy) during the perinatal
period induces enhanced reductions in DNA methylation of
fatty-acid β-oxidation genes in the postnatal mouse liver13. We
employed the microarray-based integrated analysis of methyla-
tion by isoschizomers (MIAMI)21 to analyze genome-wide DNA
methylation status in the livers of offspring derived from dams-
administered Wy dissolved in dimethyl sulfoxide (DMSO) as
vehicle (Veh) during the late gestation (from 14 to 18 days after
fertilization: e14–18) and lactation periods (from 2 to 16 days
after birth: D2–D16) (Fig. 1a). Accordingly, we sought to identify
the genes for which DNA hypomethylation status induced via
ligand-activated PPARα in the perinatal mouse liver persists into
adulthood.
To clarify whether Wy was transferred to pups via the breast
milk, we analyzed gastric contents, which mainly consisted of the
milk derived from dams, in offspring at D16 using mass
spectrometry (liquid chromatography/tandem mass spectrometry
[LC/MS-MS]). As shown in Supplementary Fig. 1, LC/MS-MS
detected the same precursor (mass-to-charge ratio [m/z], 324.06]
and product peaks (m/z, 306.04) in both a standard sample
consisting of puriﬁed Wy and milk samples from Wy-offspring
(derived from Wy-treated dams), suggesting that Wy is present in
the breast milk of dams (Supplementary Fig. 1).
We performed lipid composition analysis of milk using the
offspring gastric contents by gas chromatography (GC). GC
showed no signiﬁcant difference in lipid composition of milk
between Wy- and Veh-offspring (derived from Veh-treated
dams), suggesting that Wy administration to dams during the
lactation period did not affect milk lipid composition (Supple-
mentary Table 1).
MIAMI analysis revealed that more genes were DNA
hypomethylated in Wy-offspring relative to Veh-offspring at
D16 (Fig. 1b), and were DNA hypermethylated at 14W (14W)
(Fig. 1c). A correlation plot showing the differences at D16 (x-
axis) vs. 14W (y-axis) indicates a weak but signiﬁcant correlation
between DNA methylation status at D16 and 14W (Fig. 1d). We
found that 424 genes were DNA hypomethylated in Wy-offspring
relative to Veh-offspring at D16, and 33 genes were DNA
hypomethylated at 14W after birth (Fig. 1e). Consequently, we
identiﬁed 25 genes, which were DNA hypomethylated in Wy-
offspring relative to Veh-offspring both at D16 and 14W (Fig. 1e).
Pathway analysis of the 25 genes yielded the PPAR signaling
pathway among which 11 genes are known to be PPARα target
genes15 (Table 1).
PPARα-dependent Fgf21 demethylation in the suckling period.
Among the 11 aforementioned PPARα target genes, we focused
on FGF21, a peptide hormone which plays a critical role in reg-
ulating energy homeostasis20. To verify whether Fgf21 demethy-
lation physiologically occurs in a PPARα-dependent manner, we
examined Fgf21 methylation status in PPARα-deﬁcient (PPARα-
KO) and wild-type (WT) offspring via bisulﬁte-sequencing ana-
lysis. In silico search identiﬁed 21 CpG sites around the tran-
scription start site (TSS) of Fgf21, with two PPAR response
elements (PPRE1 and PPRE2) that are located approximately
1000 and 100 bp upstream of the TSS, respectively (Fig. 2a)22.
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There was no signiﬁcant change in Fgf21 methylation in the
livers of WT offspring during the late fetal and early postnatal
periods (e14-D2). However, there was signiﬁcant Fgf21 demethy-
lation during the suckling period (D2–D16) (Fig. 2b, c). Fgf21
demethylation was gradually induced from D16 to 4W, after
which it remains constant from 4W to 14W (Fig. 2b, c). We also
found that Fgf21 methylation status remains unchanged in the
livers of PPARα-KO offspring at all time points examined
(Fig. 2b, c). Taken together, these observations suggest that
PPARα-dependent Fgf21 demethylation physiologically occurs
during the suckling period, after which it persists into adulthood.
Fgf21 demethylation is enhanced by ligand-activated PPARα.
We found that Fgf21 demethylation is more enhanced in Wy-
offspring than in Veh-offspring at D16 and 4W, after which it
remained relatively constant until 14W (Fig. 2b, c). Notably, the
difference in Fgf21 methylation was maintained between Wy- and
Veh-offspring at 4W (36.3% and 49.5%, respectively) and 14W
(34.0% and 48.5%, respectively). These observations, taken toge-
ther, suggest that Fgf21 demethylation can be modulated and
enhanced in a PPARα ligand-dependent manner in the postnatal
mouse liver, and that the ligand-activated Fgf21 demethylation
established in early life persists into adulthood. In this study,
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Fig. 1 Genome-wide DNA methylation analysis of Wy-offspring. a Experimental protocol of genome-wide DNA methylation analysis in the liver of offspring
derived from dams-administered Wy (Wy-offspring) or DMSO (Veh-offspring) during the late gestation (e14–e18) and lactation periods (D2–D16). b, c
MIAMI analysis comparing vehicle (labeled with Cy3) with Wy (Cy5) at D16 (b) and 14W (c). Plots of log transformed values of HpaII (methylation-
sensitive, horizontal axis) and MspI signal difference (methylation-insensitive, vertical axis) between samples. The values of HpaII signal difference/MspI
signal difference judged as increased and decreased DNA methylation are above 1.4 and below 0.65, respectively. The regression line is in yellow and red
lines are located log10 1.4 and log10 0.65 of the horizontal distance from the regression line. Orange and blue circles are judged as hypermethylated and
hypomethylated, respectively. d A correlation plot showing the differences at 14W (y-axis) vs. D16 (x-axis). Genes, which are hypomethylated both at D16
and 14W are highlighted as blue circles. e Venn-diagram showing the result of MIAMI analysis. Four-hundred and twenty-four genes were DNA
hypomethylated in Wy-offspring relative to that in Veh-offspring at D16 and 33 genes at 14W, respectively. Consequently, we identiﬁed 25 genes that were
DNA hypomethylated in Wy-offspring relative to that in Veh-offspring both at D16 and 14W
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there was no signiﬁcant Fgf21 demethylation in PPARα-KO off-
spring, indicating that Wy-induced Fgf21 demethylation is
PPARα dependent (Supplementary Fig. 2a).
PPARα-dependent Fgf21 demethylation is life stage-speciﬁc.
We next examined at which life stage PPARα-dependent Fgf21
demethylation can be ligand-activated in the mouse liver. In this
study, we divided dams into two groups; one was treated with Wy
only during the late gestation period (e14–e18) and the other was
treated with Wy only during the lactation period (D2–D16)
(Fig. 3a). We found that reductions in Fgf21 methylation were
signiﬁcantly enhanced in Wy-offspring relative to Veh-offspring
during the lactation but not the late gestation period. Importantly,
when adult WT mice were treated directly with Wy for 2 weeks
after the suckling period (4–6W), there was no signiﬁcant Fgf21
demethylation from 4W to 14W (Fig. 3b). These observations
suggest that the ligand-activated PPARα-dependent Fgf21
demethylation occurs speciﬁcally during the suckling period.
Table 1 PPARα target genes which were DNA
hypomethylated at both D16 and 14W (Wy-offspring vs.
Veh-offspring)
Gene symbol Gene name
Acot1 Acyl-CoA thioesterase 1
Aqp3 Aquaporin 3
Aqp7 Aquaporin 7
Cpt1b Carnitine palmitoyltransferase 1b
Dgat1 Diacylglycerol O-acyltransferase 1
Fabp3 Fatty-acid-binding protein 3
Fgf21 Fibroblast growth factor 21
Peci Peroxisomal 3,2-trans-enoyl-CoA isomerase
Plin1 Perilipin 1
Psat1 Phosphoserine aminotransferase 1
Ucp3 Uncoupling protein 3
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Fig. 2 DNA methylation analysis of Fgf21. a Schematic representation of the promoter region of Fgf21. Open circles and gray boxes indicate CpG sites and
PPAR response elements (PPREs), respectively. Bisulﬁte-sequencing (BS) analysis region encompassing the transcription start site is indicated. b Bisulﬁte-
sequencing analysis of Fgf21 in Wy- and DMSO (Veh)-treated offspring and PPARα-KO mice. Closed and open circles indicate methylated and
unmethylated CpGs, respectively. Representative data of three independent experiments are shown. c Graphic presentation of statistical analysis of the
bisulﬁte-sequencing data. The gray-shaded box indicates the period of maternal administration of Wy or Veh, (n= 3–6 at each time point). Statistics by
one-way ANOVA with Tukey’s multiple comparison test. Data are expressed as mean± SEM. *P< 0.05; **P< 0.01; ###P< 0.001 vs. Veh-offspring
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Milk lipid components responsible for Fgf21 demethylation.
The lipid composition analysis of milk using the gastric contents
of offspring revealed that palmitic acid, oleic acid and linoleic
acid, which have been proposed as natural endogenous ligands
for PPARα23,24, are the major components of milk lipids (Sup-
plementary Table 1).
Because fatty acids in diet inﬂuence the lipid component of
breast milk of dams25, we administered fat-free diet (0% energy as
fat) and control diet (10% energy as fat) to dams during late
gestation and lactation period and analyzed Fgf21 methylation in
the liver of offspring (Supplementary Fig. 3). The lipid
composition analysis of milk using the gastric contents of
offspring derived from fat-free diet-fed dams revealed that
linoleic acid and α-linolenic acid levels were markedly reduced
relative to offspring derived from control diet-fed dams; notable,
that eicosapentaenoic acid (EPA) was not detected in the milk of
fat-free diet-fed dams (Supplementary Table 2).
However, Fgf21 methylation status of the offspring
derived from fat-free diet-fed dams was mainly unchanged
relative to that derived from control diet-fed dams both at D16
and 4W (Supplementary Fig. 3). Because the ratios of palmitic
acid, oleic acid, arachidonic acid (ARA), and docosahexaenoic
acid (DHA), in milk, which are known to be ligands for
PPARα23,24,were comparable between the offspring derived
from fed fat-free and control diet dams, it is likely that
they are responsible for physiological Fgf21 demethylation.
Moreover, as the physiological Fgf21 demethylation was induced
without EPA in the milk components, we speculated that EPA
may not be related to Fgf21 demethylation (Supplementary
Table 2).
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Fig. 3 Life stage-speciﬁc DNA demethylation of Fgf21. a Experimental protocol of maternal administration of Wy or DMSO (Veh) during the late gestation
(e14–e18) and lactation periods (D2–D16) (left). Bisulﬁte-sequencing analysis of the offspring on D16 (right) (n= 3–4 for each group). Statistics by
unpaired Student’s t-test. Data (% DNA methylation) are expressed as mean± SEM. **P< 0.01; N.S.: not signiﬁcant vs. Veh-offspring. b Experimental
protocol (top) and bisulﬁte-sequencing analysis (bottom) in mice treated with Wy or Vehicle from 4W to 6W (Wy- and Veh-mice, respectively). Bisulﬁte-
sequencing analysis of Fgf21 in Wy- and Veh-mice (bottom left). Representative data of three independent experiments are shown. Graphic presentation of
statistical analysis of the bisulﬁte-sequencing data (bottom right). The gray-shaded box indicates the period of Wy or Veh administration. (n= 4–5 per
group, statistics by one-way ANOVA with Tukey’s multiple comparison test). Data are expressed as mean± SEM. **P< 0.01; N.S., not signiﬁcant vs. Veh-
mice
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Reductions in FGF21 methylation in the fetal human liver. We
also examined human FGF21methylation status in fetal and adult
livers. The locations of PPRE (PPRE1 but not PPRE2 in the
mouse sequence), TSS, and potential CpG sites for DNA
methylation are conserved between mice and humans (Supple-
mentary Fig. 4a). In this study, FGF21 methylation was markedly
reduced in the adult liver than in the fetal liver (Supplementary
Fig. 4b), suggesting a common mechanism of developmental
programming in mammals.
Histone modiﬁcation of Fgf21 in the postnatal mouse liver.
Using chromatin immunoprecipitation (ChIP) assays (Fig. 4a),
we found that H3K4me3 and H3K27Ac, two transcriptionally
active histone marks, are enriched in Fgf21 promoter in Wy-
offspring relative to the ﬁndings in Veh-offspring at D16, when
the levels of the repressive histone marks, H3K9me2 and
H3K27me3 were roughly comparable between Wy- and Veh-
offspring (Fig. 4b). At 14W, however, there was no signiﬁcant
difference in the levels of active and repressive histone marks in
Fgf21 promoter (Fig. 4c). On the other hand, the recruitment of
PPARα was roughly equivalent between Wy- and Veh-offspring
both at D16 and 14W (Fig. 4d).
TET2 may be related to PPARα-dependent Fgf21 demethyla-
tion. We evaluated mRNA expressions for epigenetic modiﬁers
such as Ten-eleven translocation (TET) enzymes and DNA
methyltranferases (DNMTs)11,26. Postnatal ontogenic gene
expression of TET enzymes showed that Tet1 mRNA levels were
decreased in a time-dependent manner after birth, whereas both
Tet2 and Tet3 mRNA levels were increased with a peak at D16
and declined thereafter. On the other hand, both Dnmt3a and
Dnmt3b mRNA levels were gradually decreased toward adult-
hood (Fig. 5a).
We performed ChIP assays for these epigenetic modiﬁers at
D16; TET2 but not TET1 or TET3 was recruited abundantly to
Fgf21 promoter in Wy-offspring than in Veh-offspring (Fig. 5b).
On the other hand, there was no signiﬁcant difference in the
recruitment of DNMT3a and DNMT3b to Fgf21 promoter
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Fig. 4 Histone modiﬁcations of Fgf21 in Wy-offspring. a Schematic representation of the promoter region of Fgf21. Open circles and gray boxes indicate CpG
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between Wy- and Veh-offspring at D16 (Fig. 5b). In this study,
adult WT mice, when treated directly with Veh (Veh-mice) or
Wy (Wy-mice) for 2 weeks after the suckling period (4–6W),
showed no signiﬁcant difference in Fgf21 methylation status
between 4W and 6W (Fig. 3b). At 6W, there was no signiﬁcant
difference in the recruitment of TET2 to Fgf21 promoter between
Veh- and Wy-mice (Fig. 5c).
Fgf21 methylation status determines gene expression response.
We examined hepatic Fgf21 mRNA expression and serum FGF21
concentrations in Wy- and Veh-offspring. We detected sub-
stantial amounts of hepatic Fgf21 mRNA and serum FGF21
protein in Veh-offspring on D2 and D16, possibly as a result of
neonatal starvation and/or in response to milk lipid intake16,
whereas their levels were relatively low at 4W and 14W (Fig. 6a,
b). This is consistent with previous reports that hepatic Fgf21
mRNA expression and serum FGF21 concentrations are rapidly
increased upon birth, after which they remain elevated during the
suckling period and gradually decline in adulthood16,18.
We next examined whether Fgf21 methylation status affects
Fgf21 mRNA expression in adulthood upon transient PPARα
activation. There was no signiﬁcant difference in steady-state
hepatic Fgf21 mRNA levels and serum FGF21 concentrations
between Wy- and Veh-offspring (Fig. 6c, d: left). However, upon
PPARα activation by a single Wy injection, Fgf21 mRNA
expression was signiﬁcantly increased in Wy-offspring than in
Veh-offspring (Fig. 6c, d: left). There was a negative correlation
between the degree of DNA methylation (% DNA methylation)
and the induction of gene expression (Fig. 6c, d: right).
Because FGF21 expression is known to increase during fasting
as a result of PPARα activation18,22,27–29, we examined the effect
of fasting on serum FGF21 concentrations. In response to 24-h
fasting, serum FGF21 concentrations were signiﬁcantly increased
in Wy-offspring than in Veh-offspring at 14W (Fig. 6e). In this
study, there was no signiﬁcant difference in serum non-esteriﬁed
fatty-acid (NEFA) concentrations after 24-h fasting between Wy-
and Veh-offspring (Fig. 6f), suggesting that the increased
induction of serum FGF21 is due to increased responsiveness to
rather than increased levels of endogenous ligands for PPARα.
As shown in Fig. 3b, Wy- and Veh-mice displayed no
signiﬁcant change in DNA methylation status of Fgf21 at 14W.
Upon a single Wy injection at 14W, serum FGF21 concentrations
were similarly increased in both Wy- and Veh-mice (Supple-
mentary Fig. 5).
ChIP assays revealed that RNA polymerase II (Pol II) was
recruited abundantly to Fgf21 promoter of Wy-offspring relative
to Veh-offspring at D16 (Fig. 6g), suggesting active transcription
of Fgf21 in Wy-offspring relative to Veh-offspring. Upon a single
Wy injection at 14W, Pol II was recruited abundantly to Fgf21
promoter of Wy-offspring relative to Veh-offspring (Fig. 6h).
This data suggest that a modest difference in DNA methylation
status can affect transcriptional activity.
We evaluated DNA methylation ratios of each CpG site in
Fgf21 promoter at 14W (Supplementary Fig. 6a) and found that
CpG sites located downstream of the TSS (the CpG site number:
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#10–21) are sensitive to PPARα-dependent DNA demethylation.
The CpG sites but not those located upstream of the TSS were
correlated to the induction of Fgf21 expression upon the single
Wy injection (Supplementary Fig. 6b, c).
Wy-offspring exhibited less weight gain during HFD feeding.
We examined metabolic phenotypes in Wy- and Veh-offspring
during 10 weeks of high-fat diet (HFD) or normal chow diet
(NCD) feeding (4–14W) (Fig. 7a and Supplementary Fig. 7a).
Animals were classiﬁed as Veh-offspring fed NCD (Veh-NCD) or
HFD (Veh-HFD) and Wy-offspring fed NCD (Wy-NCD) or fed
HFD (Wy-HFD). In this study, we found no signiﬁcant difference
in body weight and food intake between Wy-NCD and Veh-NCD
(Supplementary Fig. 7b, c). The weights of inguinal white adipose
tissue (iWAT), epididymal WAT (eWAT), and brown adipose
tissue (BAT) were roughly comparable between the Wy-NCD and
Veh-NCD groups at 14W (Supplementary Fig. 7d). There was no
signiﬁcant difference in serum triglyceride (TG) and total cho-
lesterol (T-Chol) concentrations, or glucose tolerance
0
10
20
30
40
0 2 4 6 8 10 12 14
a b
Wy-HFD
Veh-HFD
* *
c
Wy-HFD
Veh-HFD
W
Fo
od
 in
ta
ke
 (g
/da
y)
Bo
dy
 
w
e
ig
ht
 (g
)
W
N.S.
e
Offspring
Wy14643
e0
14W
Dam
Gestation Lactation Adulthood
4W
HFD
Veh-HFD
e14 D16D2e18
0
500
1000
1500
2000
2500
0 4 8 12 16 20
ZT
0
100
200
f 14W4W
Veh-HFD
49.5%
36.3% 32.4%
Wy-HFD
44.1%
g
R
el
at
iv
e 
m
R
N
A 
le
ve
l
Serum FGF21
h
(pg
/m
l)
***
***
**
***
***
***
i
0
100
200
0
100
200
300
R
el
at
iv
e 
m
R
N
A 
le
ve
l
R
el
at
iv
e 
m
R
N
A 
le
ve
l
c-fos mRNAEgr1 mRNA
P=0.09
0
100
200
0
100
200
300
R
el
at
iv
e 
m
R
N
A 
le
ve
l
R
el
at
iv
e 
m
R
N
A 
le
ve
l
Atgl mRNAHsl mRNA
Fgf21 mRNA
eWAT
Wy-HFD
Veh-HFD
0
1
2
3
4
5
94 5 6 7 8
0
1
2
Ti
ss
ue
 w
e
ig
ht
 (m
g)
0
50
100
0
0.5
1
0
1
2
3
Ti
ss
ue
 w
e
ig
ht
 (g
)
d
Ti
ss
ue
 w
e
ig
ht
 (g
)
Ti
ss
ue
 w
e
ig
ht
 (g
)
eWAT iWAT BATLiver
*** 
N.S.
Wy-HFDVeh-HFD
N.S. N.S.
*
*
**
*
Wy-HFD
Veh-HFD
Wy-HFD
Veh-HFD
0
20
40
60
80
100
4W 14W
%
 D
N
A 
m
et
hy
la
tio
n
**
*
Wy-HFD
Veh-HFD
**
0
10
20
0 20 40 60 80 100 120 140 160 180 200
Veh-HFD Wy-HFD
eWAT
100 μm 100 μm
Adipocyte diameter (μm)
Fr
eq
ue
nc
y 
(%
)
Wy-HFD
Veh-HFD
91.8
0
50
100
Ad
ip
oc
yt
e
 d
ia
m
et
er
 (μ
m
)
*
82.9
Wy-HFD
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03038-w ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:636 |DOI: 10.1038/s41467-018-03038-w |www.nature.com/naturecommunications 9
(Supplementary Fig. 7e, f). Serum FGF21 concentrations in both
Wy-NCD and Veh-NCD were relatively low, with no appreciable
difference (Supplementary Fig. 7g).
After 10 weeks of HFD feeding, Wy-HFD gained less weight
than Veh-HFD (Fig. 7b) even though food intake was similar
(Fig. 7c). The weight of eWAT was signiﬁcantly lower in Wy-
HFD than in Veh-HFD (Fig. 7d). Histologically, adipocyte cell
size in eWAT appeared to be reduced in Wy-HFD relative to that
in Veh-HFD (Fig. 7e).
We found no signiﬁcant difference in serum TG, T-Chol,
NEFA, and adiponectin concentrations between Wy-HFD and
Veh-HFD (Supplementary Fig. 8a). The area under the curve of
the glucose tolerance test (GTT) was signiﬁcantly reduced in Wy-
HFD relative to that in Veh-HFD (Supplementary Fig. 8b).
Enhanced FGF21 expression in Wy-offspring during HFD
feeding. Bisulﬁte-sequencing analysis revealed that although
Fgf21 demethylation is marginally induced in both Wy-HFD and
Veh-HFD, the difference in Fgf21 methylation status between
Wy-HFD and Veh-HFD remains constant even after HFD
feeding (Fig. 7f).
Hepatic Fgf21 mRNA expression was signiﬁcantly higher in
Wy-HFD than in Veh-HFD at 14W (Fig. 7g). In this study, serum
FGF21 concentrations in Wy-HFD ranged 800–2000 pg/mL, and
the circadian variation in serum FGF21 concentrations was
approximately twofold higher in Wy-HFD than in Veh-HFD at
all time points examined (Fig. 7h). Consistently, the mRNA
expression of Egr1 and c-fos, which are located downstream of
Fgf2130, and that of Hsl and Atgl, which are lipolytic enzymes,
were increased in eWAT from Wy-HFD relative to those in Veh-
HFD (Fig. 7i). The mRNA expression of these genes was roughly
equivalent between Wy-HFD and Veh-HFD both in iWAT and
BAT (Supplementary Fig. 8c, d), suggesting the selective response
of fat depots in response to FGF21.
Similar phenotypes of rhFGF21- and Wy-treated HFD-fed
mice. To explore whether increased FGF21 production con-
tributes to the metabolic phenotypes in Wy-HFD, we examined
the effect of recombinant human (rh) FGF21 administration in
adult WT mice fed an HFD for 4 weeks (4–8W) (Supplementary
Fig. 9a). We optimized the rhFGF21 dose to ensure that the
increase in serum FGF21 concentrations in FGF21-treated mice
relative to that in saline-treated mice is roughly comparable to
that in Wy-HFD relative to the ﬁndings in Veh-HFD (Fig. 7h). In
this study, we found that serum FGF21 concentrations were
approximately 1300 and 400 pg/mL in FGF21- and saline-treated
mice, respectively (Supplementary Fig. 9b).
The FGF21-treated HFD-fed mice displayed signiﬁcantly lower
body weight and eWAT weight than saline-treated HFD-fed mice
(Supplementary Fig. 9c, d). Histologically, adipocyte cell size in
eWAT from FGF21-treated HFD-fed mice appeared to be smaller
than that from saline-treated HFD-fed mice (Supplementary
Fig. 9e). Egr1, c-fos, Hsl, and Atgl mRNA expression was higher in
FGF21-treated HFD-fed mice than in saline-treated HFD-fed
mice (Supplementary Fig. 9f).
Metabolic phenotypes of Wy-HFD were alleviated in FGF21-
KO. We obtained FGF21-deﬁcient (KO) mice31 and induced
DNA demethylation of all the PPARα target genes except Fgf21
by maternal administration of Wy (Fig. 8a). We examined the
metabolic phenotype of the offspring derived from FGF21-KO
dams treated with Wy and Veh during 10 weeks of HFD feeding
(4–14W) (Veh-FGF21-KO and Wy-FGF21-KO, respectively)
(Fig. 8a). As shown in Fig. 8b, we found no signiﬁcant difference
in body weight between Veh-FGF21-KO and Wy-FGF21-KO.
The weights of iWAT, eWAT, and BAT were roughly comparable
between the Veh-FGF21-KO and Wy-FGF21-KO at 14W
(Fig. 8c). Serum FGF21 was not detected in both groups, proving
systemic FGF21 deﬁciency (Fig. 8d). Histologically, adipocyte cell
size in eWAT appeared to be comparable between the Veh-
FGF21-KO and Wy-FGF21-KO groups at 14W (Fig. 8e). Con-
sistently, the mRNA expression of Egr1, c-fos, Hsl, and Atgl
showed no signiﬁcant difference between the two groups (Fig. 8f).
These observations are consistent with the notion that Fgf21 plays
a major role in the metabolic phenotypes of Wy-HFD (Fig. 7).
Discussion
This study represents the ﬁrst detailed analysis of DNA methy-
lation status of a particular gene throughout life. Hence, we
demonstrated that Fgf21 methylation status can be modulated in
a PPARα-dependent manner and that once established in early
life, the status persists into adulthood. Given that PPARα may act
as a sensor of milk lipids during the suckling period16,17, it is
likely that the suckling period provides a critical time window for
PPARα-dependent Fgf21 demethylation in response to the
maternal environment.
The detailed mechanism underlying PPARα-dependent DNA
demethylation of its target genes remains to be elucidated. A
couple of studies proposed that transcriptional factors such as
PPARγ and aryl hydrocarbon receptor (Ahr) induce DNA
demethylation by TET enzymes32,33. Given that TET2 but not
TET1 or TET3 were signiﬁcantly more abundantly recruited to
Fgf21 promoter in Wy-offspring than in Veh-offspring at D16,
TET2, an eraser of DNA methylation, may be involved in Fgf21
demethylation during the suckling period. Furthermore, under
PPARα deﬁciency, the recruitment of TET2 to Fgf21 promoter
was roughly equivalent between Wy- and Veh-offspring (Sup-
plementary Fig. 2b), thereby indicating the potential interaction
between TET2 and PPARα. In adulthood, we found no differ-
ences in the recruitment of TET2 between the mice treated with
vehicle and those treated with Wy (Fig. 5c), which may explain
that PPARα-dependent Fgf21 demethylation occurs only during
Fig. 7 Metabolic phenotypes of Wy-offspring during high-fat diet (HFD) feeding. a Experimental protocol of Veh-offspring and Wy-offspring fed HFD diet,
which are referred to as Veh-HFD and Wy-HFD, respectively. The gray-shaded box indicates the period of maternal administration of Wy or Veh. b, c Body
weight changes (b) and total food intake during HFD feeding (c) (n= 11 per group, statistics by two-way ANOVA with repeated measures). d Tissue weight
of Wy- and DMSO (Veh)-treated HFD mice at 14W (n= 11 per group). e Hematoxylin and eosin (HE) staining (top, representative image of ten individuals
per group) and quantiﬁcation of adipocyte diameter (bottom) of eWAT. Histograms of adipocyte diameter (bottom left). Horizontal lines with bilateral
squares indicate interquartile range (IQR). Arrows indicate the median values (numbers above the horizontal lines) of Veh-HFD and Wy-HFD. Statistical
analysis (bottom right) of mean adipocyte diameters are shown. Scale bar= 100 µm (n= 10 per group). f Bisulﬁte-sequencing analysis (left, representative
data of three independent experiments) and graphical presentation of statistical analysis (right, n= 4–5 per group) of Fgf21 in Wy-HFD and Veh-HFD at
4W and 14W. g Hepatic Fgf21 mRNA expression in Wy-HFD and Veh-HFD at 14W. (n= 10 per group). h Circadian variation of serum FGF21
concentrations. ZT, zeitgeber time (n= 11 per group). i Relative mRNA expression of Egr1, c-fos, Hsl, and Atgl in eWAT (n= 10 per group). Statistics by
unpaired Student’s t-test otherwise indicated. Data are expressed as mean± SEM. *P< 0.05; **P< 0.01; ***P< 0.001; N.S., not signiﬁcant vs. Veh-HFD
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Fig. 8 Analysis of FGF21-deﬁcient (KO) mice. a Experimental protocol of maternal administration of Wy or DMSO (Veh) to FGF21-KO dams during the late
gestation (e14–e18) and lactation periods (D2–D16). Offspring derived from Wy- or Veh-administered dams are referred to as Wy-FGF21-KO and Veh-
FGF21-KO, respectively. These offspring were treated with HFD diet for 10 weeks in adulthood (from 4W to 14W). b Body weight changes during HFD
feeding (n= 7–9 per group, statistics by two-way ANOVA with repeated measures). c Tissue weight of Wy- and Veh-FGF21-KO at 14W. d Serum FGF21
levels of Wy- and Veh-FGF21-KO at 14W. e Hematoxylin and eosin (HE) staining (top, representative image of 7–9 individuals per group) and
quantiﬁcation of adipocyte diameter (bottom) of eWAT. Histograms of adipocyte diameter (bottom left). Horizontal lines with bilateral squares indicate
interquartile range (IQR). Arrows indicate the median values (numbers above the horizontal lines) of Veh-FGF21-KO andWy-FGF21-KO. Statistical analysis
(bottom right) of mean adipocyte diameters± SEM are shown. Scale bar= 100 µm. f Relative mRNA expression of Egr1, c-fos, Hsl, and Atgl in eWAT, n=
7–9 per group. Statistics by unpaired Student’s t-test otherwise indicated. Data are expressed as mean± SEM. N.S., not signiﬁcant vs. Veh-FGF21-KO
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the suckling period. On the other hand, DNMT3a and 3b, which
are de novo DNMTs; writers of DNA methylation34 may not be
related to PPARα-dependent Fgf21 demethylation.
It is of great physiological signiﬁcance to identify a milk lipid
component that acts as a PPARα agonist and might thus mediate
Fgf21 demethylation.
Through milk lipid composition analysis of veh- and Wy-
treated and fat-free diet-fed dams, we speculated that the fatty
acids such as palmitic acid, oleic acid, ARA, and DHA, forming a
coordination ligand complex for PPARα, would mediate PPARα-
dependent Fgf21 demethylation.
DNA methylation ratios of CpG sites downstream of TSS, in
gene body, were signiﬁcantly different between Veh- and Wy-
offspring, suggesting that enhanced DNA demethylation via
ligand-activated PPARα could speciﬁcally occur at these CpG
sites. Since DNA methylation ratios of these CpG sites were
negatively correlated to the induction of gene expression, DNA
hypomethylation status at these CpG sites could determine the
magnitude of the gene expression response to environmental
cues. So far, possible functions of gene body or intragenic DNA
methylation has not yet been fully elucidated35. It was reported
that intragenic DNA methylation in mammalian cells initiates
formation of a chromatin structure that reduces the efﬁcacy of
Pol II elongation, thereby repressing the gene expression36, which
is compatible to our data.
Bisulﬁte-sequencing analysis also revealed that Fgf21 methy-
lation status was not monotonous, suggesting cellular hetero-
geneity in DNA methylation status. Furthermore, because the
liver consists of various types of cells such as hepatocytes, stellate
cells, Kupffer cells, and sinusoidal endothelial cells37, it may be
ideal to collect hepatocytes for bisulﬁte sequencing.
When reductions in Fgf21 methylation is more enhanced in
Wy-offspring than in Veh-offspring, hepatic induction of Fgf21 is
exaggerated in Wy-offspring upon transient PPARα activation,
during fasting and HFD feeding. Indeed, it has been known that
subtle but signiﬁcant differences in DNA methylation would
induce substantial differences in gene expression38. Thus, it is
likely that the degree of Fgf21 methylation determines the mag-
nitude of the gene expression response to environmental cues.
This is consistent with a previous report that DNA demethylation
of some mammary gland genes is induced during pregnancy, and
once established during the ﬁrst pregnancy, the DNA demethy-
lation status remains in subsequent cycles to prime the activation
of gene expression networks that promote mammary gland
function39.
It is noteworthy that the hepatic induction of FGF21 expres-
sion during fasting or HFD feeding is largely PPARα-
dependent18,20,40. In the liver, FGF21 expression is induced by
protein insufﬁciency, secondary to amino-acid deprivation, an
effect that is downstream of activating transcription factor 4
(ATF4). Carbohydrate response element–binding protein
(ChREBP), a transcription factor that regulates de novo lipo-
genesis in response to carbohydrate load, also increases hepatic
FGF21 expression20. Whether PPARα-dependent Fgf21 deme-
thylation determines the response to these PPARα-independent
environmental cues awaits further investigation.
Histone modiﬁcation is another candidate mediator of epige-
netic memory11,41,42. Indeed, a previous report illustrated that
transient neonatal activation of a nuclear receptor, namely the
constitutive androstane receptor, leads to permanent histone
modiﬁcation and induces the expression of its target genes, which
confers life-long changes in hepatic drug metabolism43. In this
study, we did not observe a signiﬁcant difference of histone
modiﬁcation at 14W, although active marks were more enriched
in Wy-offspring than in Veh-offspring on D16. However, given
the targeted nature of ChIP assays, and in light of the trends
observed in several histone marks at the targeted loci, it should be
noted that the data do not completely rule out the contribution of
histone-related gene silencing/desilencing mechanisms to the
epigenetic memory.
Importantly, the hepatic induction of FGF21 expression is
more enhanced in Wy-HFD than in Veh-HFD during 10 weeks
of HFD feeding, when Wy-HFD displays reduced body weight
and adipose tissue mass with increased expression of lipolytic
genes in eWAT relative to the ﬁndings in Veh-HFD. Even though
statistically signiﬁcant, the differences in body and eWAT weight
between Wy-HFD and Veh-HFD were relatively small. We
speculated that alternative protocols for HFD feeding, for
example, HFD feeding starts after 10W, might enhance the
difference.
Given that chronic rhFGF21 administration, which achieves
serum FGF21 concentrations roughly equivalent to those found
in Wy-HFD, reproduces some of the improved metabolic phe-
notypes of Wy-offspring, it is conceivable that Fgf21, when
upregulated due to increased DNA demethylation, contributes to
the metabolic phenotypes of Wy-HFD.
It is noteworthy that Wy-NCD does not differ signiﬁcantly
from Veh-NCD regarding steady-state Fgf21 mRNA levels and
serum FGF21 concentrations. Consistently, there was no
Ligand-activated PPARα-dependent
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Fig. 9 Schematic representation of epigenetic memory of Fgf21. Ligand-
activated PPARα induces DNA demethylation of Fgf21 in the postnatal
mouse liver; DNA methylation status of Fgf21, once established in early life,
persists into adulthood, as an epigenetic memory. In adulthood, DNA
methylation status determines the magnitude of Fgf21 expression response
to environmental cues. This may lead to the reduction of body weight and
adipose tissue mass during HFD feeding in adulthood
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03038-w
12 NATURE COMMUNICATIONS |  (2018) 9:636 |DOI: 10.1038/s41467-018-03038-w |www.nature.com/naturecommunications
appreciable difference in metabolic phenotypes between Wy-
NCD and Veh-NCD, although Wy-NCD displayed marked DNA
demethylation of Fgf21 relative to that in Veh-NCD. Because
FGF21 expression is relatively low in adulthood16,18, altered
epigenetic regulation of FGF21 expression via DNA methylation
may only be detected by pharmacologic activation of PPARα,
during fasting, or during HFD feeding. Otherwise, Fgf21 methy-
lation status, once established in early life, may represent an
adaptation mechanism against an additional environmental
challenge in adulthood.
In addition to Fgf21, it is important to identify other epigenetic
memory genes among the PPARα target genes. We investigated
transcriptional factor binding motifs in the promoter regions of
the 11 PPARα target genes, which were identiﬁed as “epigenetic
memory genes” by MIAMI analysis and found no common
consensus motifs other than PPRE. Since the microarray in
MIAMI analysis only contains 60-mer-portions of HpaII frag-
ments located in promoter regions21, it does not necessarily cover
all the CpG sites in genes. Therefore, the results of MIAMI
analysis may reﬂect DNA methylation status in a limited region
of genes, which may sometimes make a difference with that of
bisulﬁte sequencing to target a long region containing the CpG
sites. In this study, we performed bisulﬁte sequencing for Ucp3
and found that Ucp3 methylation status at D16 does not change
at 14W, and that reductions in Ucp3 methylation are enhanced in
Wy-offspring relative to Veh-offspring at D16, showing that the
difference in DNA methylation between Wy- and Veh-offspring
was maintained at 14W, which was similar to that with Fgf21
(Supplementary Fig. 10a). In this context, we previously
demonstrated reductions in DNA methylation of Ehhadh and
Acox1, two PPARα target genes responsible for fatty-acid β-oxi-
dation in the liver of Wy-offspring13. However, they were not
listed as DNA hypomethylated genes in Wy-offspring relative to
Veh-offspring both at D16 and 14W by MIAMI analysis. Indeed,
reductions in DNA methylation of Ehhadh and Acox1 were
advanced from D16 toward 14W both in Veh- and Wy-offspring,
with no signiﬁcant difference in DNA methylation status at 14W
(Supplementary Fig. 10b, c). These observations suggest that
Ehhadh and Acox1 show no epigenetic memory via a DNA
methylation mechanism. Then, what determines the epigenetic
memory? DNA methylation ratios of Fgf21 and Ucp3 at D16 were
clearly higher than that of Ehhadh and Acox1. Therefore, we
speculated that high DNA methylation ratios in the suckling
period may be related to the epigenetic memory.
In addition to Fgf21, many of the 11 PPARα target genes
identiﬁed as epigenetic memory genes are related to lipid and
glucose metabolism such as Act1, Cpt1b, Dgat1, Fabp3, Peci,
Plin1, Psat1, and Ucp3. Because these genes undergo ligand-
activated PPARα-dependent DNA demethylation during the
suckling period that persists into adulthood, it could be possible
that some of the epigenetic memory genes explain the difference
in metabolic phenotypes between Wy-HFD and Veh-HFD.
However, since the metabolic phenotypes observed in Wy-HFD
were alleviated in Wy-FGF21-KO, we speculated that Fgf21
through DNA demethylation induced during the suckling period
may be at least in part associated with the attenuation of diet-
induced obesity in adulthood.
Given its unique epigenetic properties, analysis of Fgf21
methylation status in adulthood may reﬂect to what extent DNA
demethylation is induced in response to milk lipids during the
suckling period. In this study, we found that maternal adminis-
tration of a PPARα ligand during the lactation period promotes
DNA demethylation of some PPARα target genes, suggesting that
the maternal nutritional environment can be transferred to and
stored onto the offspring’s genome as epigenetic memory via milk
lipids. The data of this study provide the proof of concept of
epigenetic modulation in early life through which the epigenetic
status of a particular gene can be modiﬁed during the suckling
period, which provides a critical time window to establish epi-
genetic memory in the DOHaD hypothesis. It is thus conceivable
that epigenetic modulation of metabolic genes by infant formulae
and/or functional food, for instance, offers a novel therapeutic
strategy to delay the onset of and/or prevent the development of
metabolic diseases, such as obesity, in adulthood.
In conclusion, this study provides the ﬁrst in vivo evidence that
FGF21 expression is epigenetically regulated via DNA methyla-
tion and that the DNA methylation status, once established in
early life, persists into adulthood, thereby contributing to the
attenuation of diet-induced obesity (Fig. 9). Thus, we propose
that FGF21 could be a key mediator of the developmental pro-
gramming of obesity.
Methods
Animals. All animal experiments were conducted in accordance with the guide-
lines of the Tokyo Medical and Dental University Committee on Animal Research,
which approved the research protocol (#0170125 A). In each experiment, we
purchased pregnant female C57BL6 mice, which were primiparous, from CLEA
Japan (Tokyo, Japan) at gestational day 13. After delivery, litter size was adjusted to
5–6 pups (all male) per dam to avoid metabolic drifts due to nutrient availability
during lactation. Maternal administration of Wy dissolved in 60% DMSO as Veh
was performed at 40 mg/kg body weight (BW)/day during gestation days 14–18
and days 2–16 of the lactation period via intraperitoneal (i.p.) injection13.
All animals were allowed free access to water and an NCD (#CE-2; 343 kcal/100
g, 12.6% energy as fat; CLEA Japan). In the HFD feeding experiments, 4-week-old
mice were fed an HFD (#D12492; 524 kcal/100 g, 60% energy as fat; Research Diets,
Inc., New Brunswick, NJ, USA) for 10 weeks (4–14W). Body weight and food
intake were measured weekly. We repeated the experiments with the same protocol
six times with reproducible results and showed the representative data from one of
the six experiments.
PPARα-KO mice44,45 (strain: B6.129S4-Pparatm1Gonz/J, stock number:
008154) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA).
Homozygous male and female PPARα-KO mice were crossed to obtain PPARα-
KO offspring. Age-matched C57BL6 mice were used as WT control mice.
FGF21-deﬁcient (KO) (strain: C57BL/6NJcl, general. FGF21-KO) mice were
kindly provided by Prof. Morichika Konishi in Kobe Pharmaceutical University,
Hyogo, Japan31. In brief, virgin homozygous male and female (23-week-old)
FGF21-KO mice were crossed to obtain FGF21-KO offspring. Maternal
administration of Wy dissolved in 60% DMSO as vehicle (Veh) was performed at
40 mg/kg body weight (BW)/day during gestation days 14–18 and 2–16 of the
lactation period via intraperitoneal (i.p.) injection. After delivery, litter size was
adjusted to ﬁve pups (all male) per dam to avoid metabolic drifts due to nutrient
availability during lactation. In the HFD feeding experiments, 4-week-old mice
were fed HFD for 10 weeks (4–14W). BW and food intake were measured weekly.
Mass spectrometry for Wy. For the Wy standard solution, we prepared 0.1 μg/
mL Wy dissolved in 50% acetonitrile. As milk samples, we used the gastric contents
of pups (Veh- and Wy-offspring), which mainly consisted of milk derived from
dams, at D16. We applied Wy standard and milk samples to LC/MS-MS operated
in a multiple reaction monitoring mode. According to PubChem, an open chem-
istry database (https://pubchem.ncbi.nlm.nih.gov/compound/5694#section=Top),
the monoisotopic mass (M) values of Wy (pirinixic acid), precursor m/z
([M +H]+), and product m/z ([M +H]+) are 323.06, 324.06, and 306.04,
respectively.
Lipid composition analysis of mouse milk. The lipid composition of mouse milk
was measured using a capillary GC method46,47. In brief, the gastric contents of
offspring at D16 were collected and total lipids were extracted using the Bligh and
Dyer method with chloroform–methanol (1:1) solution48. Fatty acids in total lipids
were methylated using boron triﬂuoride-methanol solution (14% w/v, #B1252,
Sigma-Aldrich, Saint Louis, MO, USA), and C8–C24 fatty acids were identiﬁed
using a capillary gas chromatograph–ﬂame ionization detector (#6890 N, Agilent,
Santa Clara, CA, USA) equipped with Omegawax-250 (30 × 0.25 mm, df 0.25 μm,
#24136, Sigma-Aldrich). C23:0 methyl ester (#91478, Sigma-Aldrich) was used as
the internal standard. The coefﬁcient of variation using this method was 0.4–9.9%.
Fat-free diet administration. We administered fat-free diet (#D04112303; 0%
energy as fat, Research Diets, Inc., New Brunswick, NJ, USA) and control diets
(#D12450B; 10% energy as fat, Research Diets, Inc., New Brunswick, NJ, USA) to
dams during the late gestation and lactation periods (e14–e18 and D2–D16,
respectively, for offspring). At D16, we examined the milk lipid composition in the
offspring gastric contents via gas chromatography.
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DNA methylation proﬁling. Mouse liver genomic DNA was extracted via the
standard proteinase K method. In brief, 50 mg of mouse liver were incubated with
0.5 mL of DNA digestion buffer (50 mM Tris-HCl pH 8.0, 20 mM EDTA pH 8.0,
100 mM NaCl, 1% SDS, 0.8 mg/mL Proteinase K) overnight at 55 °C. Mouse
genomic DNA was extracted with neutralized phenol/chloroform/isoamylalcohol
(25:24:1) and precipitated with one volume of 100% isopropanol. The DNA pre-
cipitate was dissolved in TE buffer and incubated at 65 °C for 15 min to resuspend
DNA. Genomic DNA was adjusted to a concentration of 0.1–0.3 µg/µL for later
analysis. Human fetal and adult liver genomic DNAs were purchased from Bio-
Chain Institute Inc. (Newark, CA, USA) and details about the materials are
described in Supplementary Table 3.
MIAMI analysis, a genome-wide analysis of DNA methylation using a gene
promoter array and methylation-sensitive restriction enzyme, was performed using a
protocol provided by Dr. Izuho Hatada (Gunma University) (http://epigenome.dept.
showa.gunma-u.ac.jp/~hatada/miami/image/MIAMI%20Protocol%20V4.pdf)49.
Brieﬂy, genomic DNAs from two samples were digested with methylation-sensitive
HpaII and methylation-insensitive MspI, followed by adaptor ligation and PCR
ampliﬁcation. Ampliﬁed DNA from one sample was labeled with Cy3 and the other
DNA sample was labeled with Cy5. After labeling, the DNAs were cohybridized to
the gene promoter arrays containing 41,332 probes. The HpaII/MspI signal difference
was determined as the methylation difference value. Values of <0.65 and >1.4
denoted DNA hypomethylation and hypermethylation, respectively13,50. DAVID v6.7
(http://david.abcc.ncifcrf.gov/) was employed for the pathway analysis. The corrected
P-values were used to judge the candidate genes (P< 0.05 was considered signiﬁcant).
Bisulﬁte-sequencing analysis. Bisulﬁte-sequencing analysis was performed as
follows. To prepare the bisulﬁte stock solution, 3.8 g of sodium metabisulﬁte
(#31609-45, Nacalai Tesque, Kyoto, Japan), 1.34 g of ammonium sulﬁte mono-
hydrate (#014-03505, Wako Pure Chemical Industries, Osaka, Japan), and 10 mL of
50% ammonium hydrogen sulﬁte solution (#014-02905, Wako) were mixed and
heated at 80 °C for dissolving. To prepare a working bisulﬁte solution (8.4 M, pH
5.2–5.3), 12 mL of the bisulﬁte stock solution were diluted with 2.28 mL of distilled
water (dH2O). Two micrograms of the genomic DNA were denatured in 0.3 N
NaOH in a total volume of 24.75 μL for 30 min at 37 °C. The sample was mixed
with 275 µL of the working bisulﬁte solution and incubated for 1 h at 70 °C in the
dark. DNA was recovered using genomic DNA puriﬁcation kit (#NPK-101, Toyobo
Life Science Department, Osaka, Japan) and dissolved in 100 µL of dH2O. The
DNA sample was mixed with 100 µL of 0.4 N NaOH (freshly prepared) and
incubated for 15 min at 37 °C. DNA was recovered by adding 150 µL of 5 M
ammonium acetate (pH 7.0), 2μL of Ethacinmate (#312-01791, Nippon Gene,
Tokyo, Japan), and 750 µL of ethanol. The DNA-containing precipitate was dis-
solved in 20 µL of 10 mM Tris-HCl/1 mM EDTA (TE, pH 7.5) and subjected to
PCR ampliﬁcation. Sequential PCR ampliﬁcation of mouse Fgf21 and human
FGF21, mouse Ucp3, Ehhadh, and Acox1 gene was performed using speciﬁc pri-
mers described in Supplementary Table 4. The reaction proﬁles were 40 cycles of
96 °C for 15 s, 59 °C (Fgf21), 56 °C (FGF21, Ucp3), 58 °C (Ehhadh) and 64 °C
(Acox1) for 30 s, and 72 °C for 60 s. The ampliﬁed fragments were ligated into
pGEM-T easy vectors (#A1360, Promega, Madison, WI, USA), and more than 13
clones were sequenced per reaction. We used a web-based quantiﬁcation tool for
the bisulﬁte-sequencing analysis of CpG methylation (http://quma.cdb.riken.jp/)51.
ChIP assay. ChIP assays were performed as follows. In brief, 200 mg of frozen
livers were homogenized in phosphate-buffered saline (PBS) containing 1% for-
maldehyde, incubated for 15 min at 37 °C and quenched with 0.125 M glycine.
Cross-linked liver tissues were washed in PBS, resuspended in lysis buffer (10%
SDS, 50 mM NaCl, 10 mM EDTA, 50 mM Tris-HCl pH 8.0, and protease inhibi-
tors) and sonicated by using a Branson 250 Digital Soniﬁer (#SFX250, Branson
Ultrasonics Corporation, Danbury, CT, USA) at 40% power amplitude. Chromatin
samples in 1-mL aliquots were incubated with Protein G-conjugated DynaBeads
(#10004D, Life Technologies, Carlsbad, CA, USA) coupled with 5 µg anti-PPARα
(a kind gift from Dr. Toshiya Tanaka, Division of Metabolic Medicine, Research
Center for Advanced Science and Technology, The University of Tokyo, Japan)52
or with appropriate antibodies (Supplementary Table 5). The dilution rate for all
antibodies is described in Supplementary Table 5. The ChIP-enriched DNA
samples were analyzed by quantitative PCR using the primer sets described in
Supplementary Table 6.
Real-time PCR analysis. Total RNA was isolated from the liver and eWAT at D2,
D16, 4W, and 14W. Real-time PCR was performed using the primer sets described
in Supplementary Table 7. The mRNA levels were normalized to those of 36B4, and
analyzed using the comparative CT method.
Biochemical assays. Serum FGF21 concentrations were determined using Rat/
Mouse (#MF2100) and Human (#DF2100) FGF21 enzyme-linked immunosorbent
assay (ELISA) kits (Quantikine ELISA; R&D Systems, Minneapolis, MN, USA).
According to the manufacturer’s instruction, recombinant mouse FGF21 had
approximately 21% cross-reactivity in the Human ELISA kit, whereas recombinant
human FGF21 had 1.4% cross-reactivity in the Rat/Mouse FGF21 ELISA kit. Serum
adiponectin concentrations were determined using a Rat/Mouse Adiponectin
ELISA kit (#MRP300, Quantikine ELISA; R&D Systems). Serum NEFA, TG, and
T-Chol levels were measured using NEFA C-Test Wako (#279-75401), TG E-Test
Wako (#432-40210), and T-Chol E-Test Wako (#439-17501) kits (Wako Pure
Chemical Industries, Ltd., Osaka, Japan), respectively.
Wy injection. Adult Wy- and Veh-offspring received a single i.p. injection of Wy
in 60% DMSO (1.2 mg/kg BW) and solvent only, respectively. Liver or blood
samples were collected 1 and 3 h after the injection to analyze Fgf21 mRNA
expression and serum FGF21 concentrations.
Glucose tolerance test. The GTT was performed via an i.p. injection of glucose at
1.0 g/kg body weight, and blood glucose levels were measured before and 30, 60, 90,
and 120 min after the injection. Blood glucose was measured using a glucometer
(Glutest PRO R; Sanwa Kagaku Kenkyusho Co., Ltd., Aichi, Japan). Serum insulin
levels were measured using an ELISA kit (Ultra Sensitive Mouse Insulin ELISA Kit,
Morinaga Institute of Biological Science, Inc., Kanagawa, Japan).
Recombinant human (rh) FGF21 administration. Four-week-old male WT mice
were housed at 25 °C and fed an HFD. rhFGF21 was purchased from PeproTech
(#100-42; Rocky Hill, NJ, USA). The bioactivity of rhFGF21 was roughly com-
parable to that of recombinant mouse FGF21 in mice53,54. Mice were administered
either saline or 0.4 mg/kg BW recombinant human FGF21 (n = 8/group) once daily
for 4 weeks.
Histological analysis. The epididymal white adipose tissue (eWAT) was ﬁxed with
neutral-buffered formalin and embedded in parafﬁn. Then, 5-µm thick sections
were stained with hematoxylin and eosin (HE). To measure adipocyte cell size,
more than 200 cells were counted per section using image-analyzing software
(WinRoof, Mitani, Tokyo, Japan). The quantitative histological analysis was per-
formed by three investigators, who had no knowledge of the slide origin.
Statistical analysis. Data are expressed as the mean± standard error of the mean
(SEM). Data were compared using a chi-squared test and Student’s t-test. Com-
parison of body weight difference was evaluated by two-way analysis of variance
(ANOVA) (between-group, within-time, and interaction of time and group).
Furthermore, comparison between groups at each week of age was evaluated by
multiple t-test with Bonferroni correction. Spearman’s rank correlation coefﬁcient
was used to evaluate correlations between variables. P< 0.05 was considered sta-
tistically signiﬁcant. Statistical analysis was performed using Prism 6 (GraphPad
Software, Inc., La Jolla, CA, USA).
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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